- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07626411
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation (ROXI-EVEREST)
A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-EVEREST)
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
연구 개요
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Clinical Trials Administrator
- 전화번호: 844-734-6643
- 이메일: clinicaltrials@regeneron.com
연구 장소
-
-
Alabama
-
Alexander City, Alabama, 미국, 35010
- 모병
- Advanced Cardiovascular
-
Dothan, Alabama, 미국, 36305
- 모병
- SEC Clinical Research
-
Fairhope, Alabama, 미국, 36532
- 모병
- Eastern Shore Research Institute
-
-
Arizona
-
Glendale, Arizona, 미국, 85306
- 모병
- West Valley Clinical Trials
-
Scottsdale, Arizona, 미국, 85260
- 모병
- Scottsdale Clinical Trials
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72205
- 모병
- Arkansas Cardiology P.A.
-
-
California
-
Covina, California, 미국, 91723
- 모병
- Valley Clinical Trials, Inc
-
Fremont, California, 미국, 94538
- 모병
- Mission Cardiovascular Research Institute
-
Huntington Beach, California, 미국, 92648
- 모병
- National Institute of California Heart and Vein Specialists
-
Inglewood, California, 미국, 90301
- 모병
- Alliance Clinical Los Angeles
-
La Jolla, California, 미국, 92037
- 모병
- Profound Research LLC at San Diego Cardiovascular Associates
-
Newport Beach, California, 미국, 92663
- 모병
- Radin Cardiovascular Medical Group
-
Northridge, California, 미국, 91325
- 모병
- Valley Clinical Trials, LLC dba Flourish Research
-
Pasadena, California, 미국, 91105
- 모병
- Southern California Heart Specialists
-
Santa Maria, California, 미국, 93454
- 모병
- FOMAT - Comprehensive Cardiovascular Care
-
Ventura, California, 미국, 93003
- 모병
- Cardiology Associates Medical Group
-
West Hills, California, 미국, 91307
- 모병
- Interventional Cardiology Medical Group
-
-
Florida
-
Boca Raton, Florida, 미국, 33434
- 모병
- Excel Medical Clinical Trials, dba Flourish Research
-
Cutler Bay, Florida, 미국, 33189
- 모병
- Nouvelle Clinical Research LLC
-
Inverness, Florida, 미국, 34452
- 모병
- Nature Coast Clinical Research - Inverness
-
Medley, Florida, 미국, 33166
- 모병
- South Florida Research Organization LLC
-
New Smyrna Beach, Florida, 미국, 32168
- 모병
- Healix Clinical Research
-
Pensacola, Florida, 미국, 32503
- 모병
- Sec Clinical Research
-
Saint Augustine, Florida, 미국, 32086
- 모병
- Flourish Research, St. Johns Center for Clinical Research
-
Sarasota, Florida, 미국, 34239
- 모병
- Cardiovascular Center of Sarasota Foundation for Research and Education
-
Winter Park, Florida, 미국, 32789
- 모병
- Clinical Site Partners, LLC DBA Flourish Research
-
-
Georgia
-
Atlanta, Georgia, 미국, 30342
- 모병
- Atlanta Clinical Research Centers
-
Atlanta, Georgia, 미국, 30310
- 모병
- Morehouse School Of Medicine
-
Johns Creek, Georgia, 미국, 30024
- 모병
- NSC Research, Inc
-
-
Indiana
-
Hobart, Indiana, 미국, 46342
- 모병
- Profound Research, Advanced Cardiovascular Care + Electrophysiology Clinic
-
Munster, Indiana, 미국, 46321
- 모병
- Profound Research, Powers Health Medical Group - Electrophysiology
-
Munster, Indiana, 미국, 46321-4054
- 모병
- Cardiovascular Research of Northwest Indiana, LLC
-
-
Louisiana
-
West Monroe, Louisiana, 미국, 71291
- 모병
- Monroe Research, LLC
-
-
Maryland
-
Ft. Washington, Maryland, 미국, 20744
- 모병
- Anderson Medical Research
-
-
Massachusetts
-
Foxborough, Massachusetts, 미국, 02035
- 모병
- K2 Medical Research, Foxboro
-
-
Michigan
-
Bloomfield Hills, Michigan, 미국, 48304
- 모병
- Profound Research, Cardiology and Vascular Associates (CAVA) - Bloomfield Hills
-
Farmington Hills, Michigan, 미국, 48334
- 모병
- Profound Research, Millennium Cardiology
-
Flint, Michigan, 미국, 48503
- 모병
- Flint Clinical Research
-
-
New York
-
Staten Island, New York, 미국, 10309
- 모병
- Super Health Pharmacy
-
-
North Carolina
-
Concord, North Carolina, 미국, 28025
- 모병
- Hawthorne Health, Moose Pharmacy of Concord
-
High Point, North Carolina, 미국, 27260
- 모병
- Peters Medical Research
-
-
North Dakota
-
Fargo, North Dakota, 미국, 58104
- 모병
- Lillestol Research LLC
-
-
Ohio
-
Marion, Ohio, 미국, 43302
- 모병
- K&R Research LLC
-
Maumee, Ohio, 미국, 43537
- 모병
- Advanced Medical Research
-
-
South Dakota
-
Rapid City, South Dakota, 미국, 57701
- 모병
- Monument Health Clinical Research
-
-
Tennessee
-
Tullahoma, Tennessee, 미국, 37388
- 모병
- Tennessee Center for Clinical Trials
-
-
Texas
-
Amarillo, Texas, 미국, 79106
- 모병
- PharmaTex Research
-
Brownsville, Texas, 미국, 78520
- 모병
- PanAmerican Clinical Research
-
Houston, Texas, 미국, 77061
- 모병
- Synergy Groups Medical
-
Houston, Texas, 미국, 77094
- 모병
- West Houston Area Clinical Trial Consultants, LLC
-
Missouri City, Texas, 미국, 77459
- 모병
- Synergy Group Medical, LLC
-
Odessa, Texas, 미국, 79761
- 모병
- Permian Research Foundation
-
Tyler, Texas, 미국, 75701
- 모병
- Tyler Cardiovascular Consultants
-
-
Utah
-
Clinton, Utah, 미국, 84015
- 모병
- Alpine Research TC
-
-
Virginia
-
Manassas, Virginia, 미국, 20109
- 모병
- Carient Heart & Vascular
-
Vienna, Virginia, 미국, 22182
- 모병
- Conquest Research
-
-
-
-
Hokkaido
-
Sapporo, Hokkaido, 일본, 062-0003
- 모병
- Hanaoka Seishu Memorial Hospital
-
-
Hyōgo
-
Kawanishi, Hyōgo, 일본, 666-0125
- 모병
- The Veritas Hospital
-
-
Ibaraki
-
Higashiibaraki District, Ibaraki, 일본, 311-3193
- 모병
- National Hospital Organization Mito Medical Center
-
Tsuchiura, Ibaraki, 일본, 300-8585
- 모병
- National Hospital Organization Kasumigaura Medical Center
-
-
Kanagawa
-
Yokohama, Kanagawa, 일본, 234-0054
- 모병
- Saiseikai Yokohama-shi Nanbu Hospital
-
-
Kyoto
-
Kyoto, Kyoto, 일본, 607-8062
- 모병
- Rakuwakai Otowa Hospital
-
-
Yokohama-shi
-
Kanagawa, Yokohama-shi, 일본, 247-0005
- 모병
- JA Tsuchiura Kyodo General Hospital
-
-
-
-
-
Longueuil, 캐나다, J4H4B9
- 모병
- Viacar Recherches Cliniques inc.
-
-
Ontario
-
Hamilton, Ontario, 캐나다, L8L 5G4
- 모병
- Premiere Clinical Trial Network
-
-
Quebec
-
Sherbrooke, Quebec, 캐나다, J1LOK3
- 모병
- Diex Recherche Inc.
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
-
Has AF or flutter (paroxysmal or persistent), not considered to be secondary to a reversible cause, and an indication for indefinite anticoagulation treatment as described in the protocol
-
Meets one of the following:
- CHA2DS2-VA [C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Systemic embolism (double points); V: Vascular disease; A: Age 65-74 years] score ≥2 and Oral Anticoagulant (OAC) naïve OR
- CHA2DS2-VA score ≥3 OR
- CHA2DS2-VA score of 2 AND at least 1 enrichment criteria as described in the protocol
-
Must have an International Normalized Ratio (INR) <2.5 at the time of randomization if taking warfarin or another Vitamin K Antagonist (VKA)
Key Exclusion Criteria:
- Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion)
- Has known moderate-to-severe mitral stenosis
- Has had a successful ablation therapy without documented recurrent AF or a participant after Left Atrial Appendage (LAA) occlusion/exclusion or plan for ablation or LAA occlusion/exclusion within the next 6 months starting from randomization
- Had an ischemic stroke within 2 days prior to randomization
- Has persistent, uncontrolled hypertension (per investigator's discretion)
- Has estimated Glomerular Filtration Rate (eGFR) <15 mL/min/1.73m2 within 30 days prior to randomization or is on dialysis or expected to be started on dialysis within the next 6 months starting from randomization
Note: Other protocol-defined Inclusion/ Exclusion criteria apply
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: REGN7508 + Placebo
|
Administered per the protocol Administered per the protocol
다른 이름들:
|
|
활성 비교기: Apixaban + Placebo
|
Administered per the protocol Administered per the protocol |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolism
기간: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding or ISTH Clinically Relevant Non-Major (CRNM) bleeding
기간: Approximately 36 months
|
Approximately 36 months
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or ISTH CRNM bleeding
기간: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, or ISTH major bleeding
기간: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or all-cause death
기간: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of ISTH major bleeding
기간: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of hemorrhagic stroke, intracerebral hemorrhage, or hemorrhagic transformation of an ischemic stroke
기간: Approximately 36 months
|
Approximately 36 months
|
|
Time to occurrence of fatal bleeding
기간: Approximately 36 months
|
Approximately 36 months
|
|
Number of ISTH major bleeding events
기간: Approximately 36 months
|
Approximately 36 months
|
|
Number of ISTH CRNM bleeding events
기간: Approximately 36 months
|
Approximately 36 months
|
|
Number of minor bleeding events
기간: Approximately 36 months
|
Approximately 36 months
|
|
Time to all-cause death
기간: Approximately 36 months
|
Approximately 36 months
|
|
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
기간: Approximately 39 months
|
Approximately 39 months
|
|
Severity of TEAEs
기간: Approximately 39 months
|
Approximately 39 months
|
|
Occurrence of Anti-Drug Antibodies (ADA) to REGN7508
기간: Approximately 36 months
|
Approximately 36 months
|
|
Magnitude of ADA to REGN7508
기간: Approximately 36 months
|
Approximately 36 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Clinical Trial Management, Regeneron Pharmaceuticals
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- R7508-CVA-24114
- 2025-521617-97-00 (씨티스)
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD 공유 기간
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 공유 액세스 기준
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- ANALYTIC_CODE
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .